Early Growth Patterns Affect CF Children’s Lung Function at Age 12, Study Shows
Children with cystic fibrosis who are able to recover from below-normal growth in their first two years are more likely to achieve normal...
Vertex’s VX-659 Triple Combo To Be Tested in Phase 3 Trial in Patients with 2 Copies of F508del Muta
Vertex Pharmaceuticals is launching a new Phase 3 trial to assess the triple combination of VX-659 plus tezacaftor (VX-661) and Kalydeco...
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Pati
RPL554 demonstrates a favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis patients LONDON, UK I March 02, 2018 I...
Gene editing – and what it really means to rewrite the code of life
We now have a precise way to correct, replace or even delete faulty DNA. Ian Sample explains the science, the risks and what the future...
ProQR and Galapagos Collaborating on a New Way of Developing Fibrosis Treatments
ProQR Therapeutics and Galapagos are working together on a new approach to treating the tissue scarring seen in cystic fibrosis. The...
Bacterial changes early in life cause cystic fibrosis in kids
Bacterial changes begin in the first few years of life leading to the formation of cystic fibrosis, which makes children repeatedly prone...